BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 27537362)

  • 21. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.
    Zhang H; Qi C; Wang A; Yao B; Li L; Wang Y; Xu Y
    J Exp Clin Cancer Res; 2013 Oct; 32(1):77. PubMed ID: 24422979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of PLAGL2 in bladder urothelial carcinoma and its relationship to lymph node metastasis and survival.
    Qu G; Xu Y; Wan SP; Yang G
    Sci Rep; 2018 Apr; 8(1):6044. PubMed ID: 29662235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in human colorectal adenocarcinoma.
    Wang YP; Guo PT; Zhu Z; Zhang H; Xu Y; Chen YZ; Liu F; Ma SP
    Oncol Rep; 2017 Apr; 37(4):1961-1970. PubMed ID: 28259923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.
    Ren GF; Tang L; Yang AQ; Jiang WW; Huang YM
    Histol Histopathol; 2014 Apr; 29(4):535-42. PubMed ID: 24222185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
    Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
    J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
    Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
    Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
    Avgeris M; Stravodimos K; Fragoulis EG; Scorilas A
    Br J Cancer; 2013 Jun; 108(12):2573-81. PubMed ID: 23703249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
    Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
    Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
    Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
    Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
    Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
    Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
    Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
    PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.
    Zhang Z; Xie H; Zhu S; Chen X; Yu J; Shen T; Li X; Shang Z; Niu Y
    Med Sci Monit; 2018 Nov; 24():8190-8197. PubMed ID: 30427826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
    Mortezavi A; Salemi S; Rupp NJ; Rüschoff JH; Hermanns T; Poyet C; Randazzo M; Simon HU; Moch H; Sulser T; Wild P; Eberli D
    Oncotarget; 2017 May; 8(19):31765-31774. PubMed ID: 28423666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
    Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
    Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.
    Ihlaseh-Catalano SM; Drigo SA; de Jesus CM; Domingues MA; Trindade Filho JC; de Camargo JL; Rogatto SR
    Histopathology; 2013 Nov; 63(5):678-85. PubMed ID: 24025158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.